Investigator initiated trial seeks to validate safety, efficacy of the NanoKnife System in treating targeted tumors while reducing or delaying need for radical intervention Approximately 40% of all ...
Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...
AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation. The clearance for the NanoKnife System for prostate ...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
AngioDynamic’s NanoKnife device uses electrodes to kill cancer cells. The surgery for prostate cancer takes about an hour. COLONIE — Latham-based medical technology company AngioDynamics is ramping up ...
NanoKnife delivers a localized electrical pulse that can treat prostate cancer. Developed by medical device firm AngioDynamics and cleared by the Food and Drug Administration in December 2024, it ...
Hosted on MSN
AngioDynamics targets 14%-16% MedTech growth for fiscal 2025 driven by thrombectomy and NanoKnife adoption
CEO Jim Clemmer highlighted strong Q3 performance with total revenue reaching $72 million, reflecting over 9% year-over-year growth. MedTech revenue grew by 22%, with continued success across ...
An announcement from AngioDynamics ( (ANGO)) is now available. Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment ...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results